Ideaya Biosciences (IDYA) announced the clearance of an investigational new drug application with the FDA for the initiation of a Phase 1 clinical trial to evaluate IDE849, a potential first-in-class delta-like ligand 3-targeting Topo-I-payload antibody drug conjugate program, in solid tumors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IDYA:
- Ideaya Biosciences reports Q1 EPS (82c), consensus (69c)
- IDEAYA Biosciences’ Trial Expansion and Regulatory Uncertainties Lead to Hold Rating
- IDEAYA Biosciences: Promising Prospects with Strategic Phase 3 Trial and Key Data Catalysts
- IDEAYA Biosciences: Promising Outlook with Regulatory Alignment and Strategic Expansion in Clinical Trials
- Ideaya trial design consisent with guidance, says Oppenheimer